Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Standard

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. / EMPA-REG OUTCOME Investigators.

In: Stroke, Vol. 48, No. 5, 05.2017, p. 1218-+.

Research output: Contribution to journal › Article › peer-review

BibTeX

@article{4748c3fbcb324e75990f115089207e6b,

title = "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk",

abstract = "Background and Purpose-In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin added to standard of care in patients with type 2 diabetes mellitus and high cardiovascular risk reduced the risk of 3-point major adverse cardiovascular events, driven by a reduction in cardiovascular mortality, with no significant difference between empagliflozin and placebo in risk of myocardial infarction or stroke. In a modified intent-to-treat analysis, the hazard ratio for stroke was 1.18 (95% confidence interval, 0.89-1.56; P= 0.26). We further investigated cerebrovascular events.Methods-Patients were randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo; 7020 patients were treated. Median observation time was 3.1 years.Results-The numeric difference in stroke between empagliflozin and placebo in the modified intent-to-treat analysis was primarily because of 18 patients in the empagliflozin group with a first event > 90 days after last intake of study drug (versus 3 on placebo). In a sensitivity analysis based on events during treatment orConclusions-In patients with type 2 diabetes mellitus and high cardiovascular risk, there was no significant difference in the risk of cerebrovascular events with empagliflozin versus placebo.",

keywords = "blood pressure, cardiovascular diseases, hematocrit, stroke, type 2 diabetes mellitus, ISCHEMIC-STROKE, FOLLOW-UP, METAANALYSIS, MORTALITY, OUTCOMES, TRIAL",

author = "{EMPA-REG OUTCOME Trial} and Bernard Zinman and Inzucchi, {Silvio E.} and Lachin, {John M.} and Christoph Wanner and David Fitchett and Sven Kohler and Michaela Mattheus and Dipl Biomath and Woerle, {Hans J.} and Broedl, {Uli C.} and Johansen, {Odd Erik} and Albers, {Gregory W.} and Diener, {Hans Christoph} and D. Aizenberg and M. Ulla and J. Waitman and {De Loredo}, L. and J. Farias and H. Fideleff and M. Lagrutta and N. Maldonado and H. Colombo and {Ferre Pacora}, F. and A. Wasserman and L. Maffei and R. Lehman and J. Selvanayagam and M. d'Emden and P. Fasching and B. Paulweber and H. Toplak and A. Luger and A. Tiburcio and S. Gupta and S. Park and Y. Kim and J. Yang and D. Kim and S. Lee and A. Petrov and K. Nikolaev and V. Potemkin and A. Bystrova and N. Tarasov and A. Obrezan and A. Khokhlov and C. Huang and J. Chen and J. Wang and S. Zotov",

year = "2017",

month = may,

doi = "10.1161/STROKEAHA.116.015756",

language = "Английский",

volume = "48",

pages = "1218--+",

journal = "Stroke",

issn = "0039-2499",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

RIS

TY - JOUR

T1 - Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

AU - EMPA-REG OUTCOME Trial

AU - Zinman, Bernard

AU - Inzucchi, Silvio E.

AU - Lachin, John M.

AU - Wanner, Christoph

AU - Fitchett, David

AU - Kohler, Sven

AU - Mattheus, Michaela

AU - Biomath, Dipl

AU - Woerle, Hans J.

AU - Broedl, Uli C.

AU - Johansen, Odd Erik

AU - Albers, Gregory W.

AU - Diener, Hans Christoph

AU - Aizenberg, D.

AU - Ulla, M.

AU - Waitman, J.

AU - De Loredo, L.

AU - Farias, J.

AU - Fideleff, H.

AU - Lagrutta, M.

AU - Maldonado, N.

AU - Colombo, H.

AU - Ferre Pacora, F.

AU - Wasserman, A.

AU - Maffei, L.

AU - Lehman, R.

AU - Selvanayagam, J.

AU - d'Emden, M.

AU - Fasching, P.

AU - Paulweber, B.

AU - Toplak, H.

AU - Luger, A.

AU - Tiburcio, A.

AU - Gupta, S.

AU - Park, S.

AU - Kim, Y.

AU - Yang, J.

AU - Kim, D.

AU - Lee, S.

AU - Petrov, A.

AU - Nikolaev, K.

AU - Potemkin, V.

AU - Bystrova, A.

AU - Tarasov, N.

AU - Obrezan, A.

AU - Khokhlov, A.

AU - Huang, C.

AU - Chen, J.

AU - Wang, J.

AU - Zotov, S.

PY - 2017/5

Y1 - 2017/5

N2 - Background and Purpose-In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin added to standard of care in patients with type 2 diabetes mellitus and high cardiovascular risk reduced the risk of 3-point major adverse cardiovascular events, driven by a reduction in cardiovascular mortality, with no significant difference between empagliflozin and placebo in risk of myocardial infarction or stroke. In a modified intent-to-treat analysis, the hazard ratio for stroke was 1.18 (95% confidence interval, 0.89-1.56; P= 0.26). We further investigated cerebrovascular events.Methods-Patients were randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo; 7020 patients were treated. Median observation time was 3.1 years.Results-The numeric difference in stroke between empagliflozin and placebo in the modified intent-to-treat analysis was primarily because of 18 patients in the empagliflozin group with a first event > 90 days after last intake of study drug (versus 3 on placebo). In a sensitivity analysis based on events during treatment orConclusions-In patients with type 2 diabetes mellitus and high cardiovascular risk, there was no significant difference in the risk of cerebrovascular events with empagliflozin versus placebo.

AB - Background and Purpose-In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin added to standard of care in patients with type 2 diabetes mellitus and high cardiovascular risk reduced the risk of 3-point major adverse cardiovascular events, driven by a reduction in cardiovascular mortality, with no significant difference between empagliflozin and placebo in risk of myocardial infarction or stroke. In a modified intent-to-treat analysis, the hazard ratio for stroke was 1.18 (95% confidence interval, 0.89-1.56; P= 0.26). We further investigated cerebrovascular events.Methods-Patients were randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo; 7020 patients were treated. Median observation time was 3.1 years.Results-The numeric difference in stroke between empagliflozin and placebo in the modified intent-to-treat analysis was primarily because of 18 patients in the empagliflozin group with a first event > 90 days after last intake of study drug (versus 3 on placebo). In a sensitivity analysis based on events during treatment orConclusions-In patients with type 2 diabetes mellitus and high cardiovascular risk, there was no significant difference in the risk of cerebrovascular events with empagliflozin versus placebo.

KW - blood pressure

KW - cardiovascular diseases

KW - hematocrit

KW - stroke

KW - type 2 diabetes mellitus

KW - ISCHEMIC-STROKE

KW - FOLLOW-UP

KW - METAANALYSIS

KW - MORTALITY

KW - OUTCOMES

KW - TRIAL

U2 - 10.1161/STROKEAHA.116.015756

DO - 10.1161/STROKEAHA.116.015756

M3 - статья

VL - 48

SP - 1218-+

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 5

ER -

ID: 87876488